Clincosm LogoSign in Get a demo

Specimen Banking From Patients With Lung Cancer

Sponsor
University of Colorado, Denver (Other)
Overall Status
Recruiting
CT.gov ID
NCT01585675
Collaborator
National Cancer Institute (NCI) (NIH)
1,000
Enrollment
1
Location
355.9
Duration (Months)
2.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of the protocol is to develop a comprehensive specimen banking program from patients with lung cancer for future translation research, which will enable the investigators to detect lung cancer earlier, develop better therapies and explore screening and prevention strategies.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The aims of the study are as follows: 1) to continue to unravel the complex biology of lung cancer 2) to identify early detection and prognostic markers to guide therapeutic decision 3) to define markers of response and/or resistance to drug therapy, and 4) to identify new therapeutic and prevention targets.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Specimen Banking From Patients With Lung Cancer
    Study Start Date :
    Nov 1, 2005
    Anticipated Primary Completion Date :
    Jul 1, 2035
    Anticipated Study Completion Date :
    Jul 1, 2035

    Arms and Interventions

    Arm Intervention/Treatment
    Diagnosis/treatment of lung cancer

    Specimen Banking

    Outcome Measures

    Primary Outcome Measures

    1. Development of a comprehensive specimen banking program from patients with lung cancer for future translational research. [6 years]

      No statistical analysis will be applied to the overall collection of samples. Rather, each project that utilized tissue bank resources will require an appropriate statistical plan to be submitted along with the initial tissue request.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer.

    2. Oral and written informed consent

    Exclusion Criteria:
    1. Any individual who does not give oral and written consent for participation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Colorado Cancer Center Aurora Colorado United States 80045

    Sponsors and Collaborators

    • University of Colorado, Denver
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Adriaan VanBokhoven, PhD, University of Colorado, Denver

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Colorado, Denver
    ClinicalTrials.gov Identifier:
    NCT01585675
    Other Study ID Numbers:
    • 04-0688.cc
    • P50CA058187
    First Posted:
    Apr 26, 2012
    Last Update Posted:
    Nov 22, 2021
    Last Verified:
    Nov 1, 2021
    Keywords provided by University of Colorado, Denver
    Lung Cancer
    Additional relevant MeSH terms:
    Lung Neoplasms

    Study Results

    No Results Posted as of Nov 22, 2021